Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations. The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Period	PE Ratio
2020-12-31	-18.34
2021-12-31	-31.80
2022-12-31	-24.30
2023-12-31	-27.68
2024-12-31	-25.12
2025-12-31	-34.36

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TNGX	$29.89	+0.81%	0.74M
3
4
5

Tango Therapeutics Inc. (TNGX) PE Ratio

PE Ratio Data

Get Tango Therapeutics Inc. Data in Excel

More TNGX Financial Data